Leerink Partners maintains Viridian Therapeutics at Outperform, raises price target to $54 from $50

Leerink Partners kept its Outperform rating on Viridian Therapeutics and increased its price target to $54 from $50, citing an 85.9% upside from the Nov 4 close of $29.05. Recent analyst targets for the company range from $33 to $42.

Original reporting
Published Nov 5, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leerink Partners maintains Viridian Therapeutics at Outperform, raises price target to $54 from $50 — source image
Decision brief

The 30-second read

$VRDNBullishMed
01

Why it matters

The upgrade may trigger short covering and new buying, modestly lifting the share price.

02

Market read

A price‑target increase is a fresh, material piece of information for VRDN, offering a short‑term trading edge.

03

What to watch

Potential dilution from future financing rounds not addressed.

Relevance 6/10Novelty 5/10Timing: today

Background

Analyst rating actions are a common catalyst for small‑cap biotech stocks.

Company-level read

Ticker impact

$VRDNBullishHigh confidence
Context

Leerink Partners raised its price target on Viridian Therapeutics to $54, indicating a bullish outlook.

Expected impact

upward pressure as investors price in the higher target.

Evidence & confidence

Target increase from $50 to $54 signals confidence in near‑term performance, likely prompting buying interest.

Market effects

May lift sentiment in the biotech/therapeutics sector.

Limited to U.S. biotech investors.

Minimal global impact.

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • Leerink Partners

    Equity research firm that issued the rating upgrade.

  • Viridian Therapeutics

    Biotech company focused on therapeutic development.

Related articles

$VRDNMedAI 8/10

Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says

Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.

$VRDNMedAI 8/10

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing - VRDN-008, a half-life extended FcRn inhibitor, demonstrated deep and sustained IgG reduction through 8 weeks after sub

$VRDNHighAI 8/10

Viridian reports phase 1 results for VRDN-008 autoimmune drug

Viridian Therapeutics (VRDN) reported phase 1 trial results for VRDN-008, showing a 74% reduction in IgG and a half-life of 15-18 days. No serious adverse events were observed. The company plans to start pivotal trials in 2027, targeting myasthenia gravis first. VRDN-008 will be administered using Enable Injections’ enFuse device, licensed exclusively by Viridian.